Cosmetic cross-reference

Polysorbate 80

CAS 9005-65-6

Polysorbate 80 (CAS 9005-65-6) is a pharmaceutical compound with 0 bioactivity targets and 105 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
0
SOURCE DrugCentral
Adverse signals
105
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE DrugCentral 055904D152D6

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Polysorbate 80
CAS Number
9005-65-6
UNII
6OZP39ZG8H
ChEMBL ID
CHEMBL1697847
DrugCentral Struct ID
2227
Source Match
DrugCentral (CAS), FDA GSRS (UNII)
Synonyms and normalized names
PEG-20 SORBITAN OLEATE
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE DrugCentral 2 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Haemolytic uraemic syndrome 11 65.261 10018932
Capillary leak syndrome 10 58.846 10007196

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE NLM RxNorm 5 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
PEG-20 SORBITAN OLEATE 8560 SU MTHSPL
polysorbate 80 8560 SU MTHSPL
POLYSORBATE 80 8560 SU MTHSPL
Polysorbate 80 8560 SU MTHSPL
polysorbate 80 8560 IN RXNORM
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Polysorbate 80 used for in pharmaceutical contexts?

Polysorbate 80 (CAS 9005-65-6) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Polysorbate 80?

Polysorbate 80 has 105 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Haemolytic uraemic syndrome, Capillary leak syndrome, Balance disorder, Bladder disorder, Blood calcium decreased. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Polysorbate 80 also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Polysorbate 80 with EU status "permitted".

What clinical phase is Polysorbate 80 in?

No phase 1-4 clinical development badge is rendered for Polysorbate 80 because the matched compound identifier rows do not contain a max-phase value.